NRG Administrative Core Abstract The NRG Oncology (NRG) Administrative Core provides the leadership and infrastructure necessary to support the largest portfolio of clinical trials among the adult groups in the NCI National Clinical Trail Network (NCTN), a membership encompassing over 220 main member sites ? including nearly every Lead Academic Participating Site (LAPS) and a robust contribution to the overall management and success of the NCTN. NRG utilizes a highly successful multiple-PI model to provide remarkably capable leadership and scientific oversight, dynamic committee leadership and mentoring, knowledgeable and experienced administrative and operational leadership, and appropriate associated support. NRG, a group formed only four years ago, has leveraged the strengths of its legacy groups to form an integrated, modern clinical trials organization addressing specific populations within the NCTN. It is notable that NRG remained highly productive in all realms even while navigating the merger of the three legacy groups, a testament to the remarkable leadership of NRG and the thoughtful organizational structure put into place. In addition to supporting its own goals, NRG is a highly collaborative member of the NCTN. NRG co-led a number of trials with other groups, championed sixteen studies from other groups, participated in numerous NCI-appointed steering committees, workgroups, and task forces, and led the development of new remote monitoring standards. NRG has the leadership and infrastructure in place to continue to support the clinical trial and membership goals as well as continue to serve as engaged stakeholders in the overall management and success of the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA180868-07S1
Application #
10166779
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Abrunhosa-Branquinho, André N; Bar-Deroma, Raquel; Collette, Sandra et al. (2018) Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial ""concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma"": Individual case review analysis. Radiother Oncol 127:292-298
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180
Roach, Mack; Moughan, Jennifer; Lawton, Colleen A F et al. (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 19:1504-1515
Mamounas, Eleftherios P; Tang, Gong; Paik, Soonmyung et al. (2018) 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Res Treat 168:69-77
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Timmerman, Robert D; Paulus, Rebecca; Pass, Harvey I et al. (2018) Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol 4:1263-1266

Showing the most recent 10 out of 357 publications